Slide 1: Pfizer Pflash: A Spotlight on Cancer Cachexia and Ponsegromab
Pfizer Pflash: A Spotlight on Cancer Cachexia and Ponsegromab an investigational monoclonal antibody targeting growth differentiation factor-15 (GDF-15) Classified – Confidential 3
Slide 2: Forward-Looking Statements and Other Notices
Our discussions during this presentation will include forward-looking commercial success, demand, availability of supply, and competitive statements that are subject to substantial risks and uncertainties that and market dynamics. Forward-Looking could cause actual results to differ materially from
Slide 3: Today's Speakers
Today’s Speakers Francesca Hosted by Francesca DeMartino Charlotte Allerton William Sessa Aditi Saxena Head, Discovery & Early Chief Scientific Officer, VP, Clinical Research Chief Investor Relations Officer Development Internal Medicine Head, Internal Medicine 5 5
Slide 4: GDF-15 is a Global Stress Regulator that Drives Cachexia
GDF-15 is a Global Stress Regulator that Drives Cachexia1 Goal: neutralization of GDF-15 with ponsegromab to inhibit biological pathways driving cachexia Ponsegromab: An Investigational Agent Designed to Inhibit the GDF-15 Signaling that Drives Cachexia GDF-15 GDF-15 Binding GDF-15 Secreted Elevated
Slide 5: GDF-15 is a Global Stress Regulator that Drives Cachexia
GDF-15 is a Global Stress Regulator that Drives Cachexia1 Goal: neutralization of GDF-15 with ponsegromab to inhibit biological pathways driving cachexia Ponsegromab: An Investigational Agent Designed to Inhibit the GDF-15 Signaling that Drives Cachexia Ponsegromab GDF-15 GDF-15 Binding GDF-15 Secre
Slide 6: Phase 2 Proof-of-Concept Trial
Phase 2 Proof-of-Concept Trial Phase 2 Study with Once Every 4 Weeks Subcutaneous Dosing for 12 Weeks1 N = 187 Study Population Ponsegromab 400 mg Cachexia with: Ponsegromab 200 mg • NSCLC • Pancreatic Cancer, or R Ponsegromab 100 mg • Colorectal Cancer 1:1:1:1 Plus Elevated GDF-151 Placebo Endpoint
Slide 7: Primary Endpoint Met: Dose-Dependent Weight Gain with Ponsegromab
Primary Endpoint Met: Dose-Dependent Weight Gain with Ponsegromab Ponsegromab was generally considered safe & well tolerated with increases in body weight at all doses tested in Ph 2 Placebo-Adjusted Weight Gain Exceeds 5% in 400 mg Dose Group at 12 Weeks1 Weight Gain >5% Suggested by Cancer Cachexi
Slide 8: Improvements Across PRO & Functional Domains at Top Dose
Improvements Across PRO & Functional Domains at Top Dose Improvements across patient-reported symptoms, overall physical activity, and muscle mass vs. placebo Secondary Endpoints & Additional Analyses: 400 mg Ponsegromab Dose Group1 Placebo-Adjusted Change from Endpoint Baseline at Week 12, Modeled
Slide 9: Ponsegromab in Cancer Cachexia: Summary
Ponsegromab in Cancer Cachexia: Summary 1 Potential to Improve Body Composition & Quality of Life1 2 May Enhance Cancer Treatment Tolerance 3 Aim to Start Registration- Enabling Study in 2025 4 Broader Potential with Ph 2 Heart Failure Trial Ongoing 1. As assessed in Phase 2 by the Anorexia and Cach
Slide 10: Q&A Session
Q&A Session Francesca Francesca DeMartino Charlotte Allerton William Sessa Aditi Saxena Chief Investor Relations Head, Discovery & Early Chief Scientific Officer, VP, Clinical Research Officer Development Internal Medicine Head, Internal Medicine 12 12